• Journal of the Korean Society of Food Science and Nutrition
• /
• v.36 no.7
• /
• pp.902-907
• /
• 2007

This study was carried out to find the effect of ${\gamma}$ -irradiation on the physical properties of alginic acid and ${\lambda}$-carrageenan solution. Alginic acid and ${\lambda}$-carrageenan aqueous solution were irradiated with $Co^{60}$ ${\gamma}$ -rays in dosages ranging from 3 to 100 kGy, and then the molecular weight, viscosity and color were measured. The molecular weight of alginic acid and ${\lambda}$-carrageenan solution were decreased as the ${\gamma}$ -irradiation dosage increased. In addition, the viscosity of irradiated alginic acid and ${\lambda}$-carrageenan solution were decreased depending upon the ${\gamma}$ -irradiation dosage, too. The high dosage irradiated alginic acid and ${\lambda}$-carrageenan solution's color were changed to yellow. These results suggest that low dosage of ${\gamma}$ -irradiation from 3 to 20 kGy is a very effective method for producing low-molecular alginic acid and ${\lambda}$-carrageenan.

• Tuberculosis and Respiratory Diseases
• /
• v.44 no.6
• /
• pp.1285-1295
• /
• 1997

Background : EGFR is one of the initial step in signal transduction pathway about multistep carcinogenesis. It is homologous to oncogene erbB-2 and is the receptor for EGF and TGF alpha. EGFR has important role in the growth and differentiation of tumor cells. So, EGFR in non-small cell lung cancer was examined to search for possible evidence as clinical prognostic factor. Methods : To investigate the role of EGFR in lung cancer, the author performed immunohistochemical stain of EGFR on 57 resected primary non-small cell lung cancer specimens. And the author analyzed the correlation between EGFR expression, clinical parameters, Sand $G_1$ phase fraction and survival. Results : 1) EGFR were detected in 56% of total 57 patients (according to histologic type, squamous cancer 50%, adenocarcinoma 63%, large cell cancer 75%) (according to TNM stage, stage I 64%, stage II 38%, stage III 55%) (according to cellular differentiation, well 50%, moderately 52%, poorly 65%). All differences were insignificant 2) Using the flow cytometric analysis, mean S-phase fraction of EGFR (+) and (-) group were 22.3(${\pm}10.5$)%. 18.0(${\pm}10.9$)% (p>0.05), mean $G_1$-phase fraction of EGFR (+) and (-) group were 68.4(${\pm}11.6$)%, 71.1(${\pm}12.8$)%, (p>0.05) 3) Two-year survival rate of EGFR (+) and (-) group were 53%, 84%, median survival time of EGFR (+) and (-) group were 26, 53 months. (p<0.05, Kaplan-Meier, generalized Wilcox) Conclusion : EGFR immunostaining may be a simple and useful method for survival prediction in non-small cell lung cancer.